Trial Profile
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jun 2021
Price :
$35
*
At a glance
- Drugs Cagrilintide (Primary) ; Semaglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 13 May 2021 Results presented at the 28th annual European Congress on Obesity
- 04 May 2021 Results published in the Internet Document
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society